Medicaid

Therma Bright Submits Updated FDA 510K Application Requesting Correction of Venowave Device’s Intended Use, Labeling, and Description

Toronto, Ontario--(Newsfile Corp. - September 7, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer...

Sickle Cell Warrior Program from The National Marrow Donor Program® (NMDP)/Be The Match® Expands Access to Bone Marrow Transplant as a Curative Treatment

During Sickle Cell Awareness Month, NMPD/Be The Match reminds individuals to visit SickleCellConnect.com to access essential resources, learn more about...

Quantum Health Announces New Clinical Advisory Boards To Expand Musculoskeletal and Behavioral Health Clinical Support for Members

Quantum Health’s newly added clinical advisory boards will launch in 2024 to expand the company’s strategic clinical guidance for musculoskeletal...

Better Life Partners Raises $26.5 Million in Series B Financing to Amplify and Scale its Hybrid Whole-Health Solutions for Substance Use Disorders

Funding will expand company’s technology-enabled, alternate-payment care model, bringing its innovative and effective approach to more people in needBOSTON, Aug....

Concert Health Joins athenahealth’s Marketplace Program to Give Providers and Patients Access to High-Quality Behavioral Health Services

Integration will allow healthcare providers to refer patients directly to Concert’s team of expert cliniciansSAN DIEGO--(BUSINESS WIRE)--#behavioralhealth--Concert Health, a leading...

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA...

Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

TARRYTOWN, N.Y., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency...

error: Content is protected !!